fbpx
Menu

Phoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu

Share

Phoenix Life Sciences International Limited (OTCMarkets: PLSI) (Phoenix Life), an international adaptive healthcare solutions company, today announced that it has received an import certificate from the Republic of Vanuatus Minister of Health to bring its cannabis diabetes drug Phoenix Metabolic into the country for clinical trials. With this certificate, we look forward to playing a pivotal role in decreasing the size of the global diabetes epidemic, said Phoenix Life Sciences International CEO Martin Tindall. The Republic of Vanuatu just took its first steps to legalize medical cannabis throughout the nation, and we are thrilled to be at the forefront of the industry during this historic time. Phoenix Life can now import its cannabis-based diabetes drug into Vanuatu and the company hopes to soon announce the launch of clinical trials for its first 1,000 patients. In the Republic of Vanuatu, a South Pacific island nation comprised of roughly 80 islands, about 13 percent of the population has diabetes. That translates to about 35,000 of the 265,000 residents, making diabetes the largest cost to the nations healthcare system. Phoenix Metabolic has the potential to significantly decrease Vanuatus yearly cost of diabetes treatments while providing a natural, safer alternative to traditional pharmaceutical medications. This certificate is the first step in transforming the health of an entire island nation based on a comprehensive, scientific approach to modern illness and disease prevention, said Dr. Philip Blair, Diabetes Director of the Phoenix Life Sciences International Medical Advisory Council. Phoenix Life utilizes a vertically-integrated operation to produce its medical cannabis pharmaceutical products and ensure maximum efficacy. The company aims to partner with the single-payer healthcare systems of both established and emerging economies to conduct medical studies on cannabis for diabetes …

[Read on via official release]

Source: US SEC
View full document:
EX-993_of_8-K_for_Phoenix_Life_Sciences_International_Limited__8-K-11-23-2018